TrialRheumatology (Oxford, England)2023

Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study.

Andrew Östör et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.